Unveiling of CANTAB Mobile Alzheimer's Test
Print
EmailCambridge Cognition announces the launch of CANTAB® Mobile, a new CE approved Class II medical device, to aid early detection of Alzheimer's disease.
With CANTAB® Mobile, healthcare professionals can now carry out a simple, objective and accurate cognitive assessment in around 10 minutes. The automated scoring for the test works by comparing the patient's test results with those of thousands of other people who have performed the test.
This test can detect the earliest signs of dementia before the damage is done, so that more effective interventions can be made to prolong the patient's independence.Cambridge Cognition's touch-screen cognitive tests, known as CANTAB®, have been used in over 700 peer-reviewed publications and around the world in academic research and by the pharmaceutical and nutraceutical industries. Following 25 years of validation research, the CANTAB® Paired Associates Learning (PAL) test is now being launched, for the first time, into mainstream primary care. The new mobile-platform version of this test will be available to GPs in less than a year following successful trials in NHS primary and secondary care settings. The test will allow GPs to triage patients presenting memory problems quickly, simply and accurately.
Over the last 25 years, Cambridge Cognition’s touch-screen cognitive tests, known as CANTAB®, have been cited in over 700 peer-reviewed publications and used around the world in academic research and by the pharmaceutical and nutraceutical industries in numerous clinical trials and research. Now for the first time, CANTAB will also be launched into mainstream primary care. The test will allow GPs to triage patients presenting with memory problems quickly, simply and accurately. Traditionally, memory screening is carried out by GPs using a pencil and paper test, most commonly the mini mental state exam (MMSE). Whilst a familiar tool, the MMSE can be lengthy to conduct and obliges the physician to follow a relatively complex administration and scoring system.
“The technologies we are developing today and placing on tablet platforms such as the iPad will enable effective patient identification and stratification to help target treatments more efficiently – not just pharmaceutical but also lifestyle, nutritional and social care interventions,” says Andrew Blackwell, CSO, speaking at the NeuroTech conference in Helsinki today (September 8). “We believe that these assessments are an important tool to ensure that we all can enjoy optimal cognitive health and wellbeing throughout life – and that this is every bit as important as our physical health.
“The CANTAB Mobile pipeline we are working on starts with our dementia product and will expand to include the common cognitive disorders typically seen by the community physician; providing tools that quickly and accurately assess cognitive health through all phases of life.
“Our aim is to provide technologies that assist in patient evaluation for General Practitioners, Family Physicians as well as clinical specialists. Increasingly, our customers also include military and educational institutions; and we believe that in future, employers, insurers and consumers will feature among the groups we serve.”
Related Videos & Articles
More Information
About Cambridge Cognition:
The CANTAB® neuropsychological tests were developed 25 years ago at the University of Cambridge by Professors Robbins and Sahakian, to enable detailed translational assessment and evaluation of cognitive function. Lesion, neuroimaging, clinical and psychopharmacological studies have enabled a unique understanding of the structural, clinical and biochemical sensitivities of each of the tests.
CANTAB was commercialised as Cambridge Cognition in 1994 and has become the world leader in computerised cognitive testing in its field. It has been used by more than 600 academic institutions worldwide and quoted in over 700 peer-reviewed publications. This immense body of work stretching back over the last 25 years gives CANTAB an unrivalled scientific heritage and degree of validation.
To receive news on CANTAB or for GPs to register for our beta programme, please fill in the form and we will keep you up to date with the latest news.
The British, VC-backed company was spun out of the University of Cambridge, with products based on the ground-breaking work of world-leading neuropsychologists from the University of Cambridge: Professors Trevor Robbins and Barbara Sahakian over 25 years ago. It is headquartered in Cambridge, UK and Cambridge, Massachusetts, US. For more information visit www.camcog.com.
Source:
.
